Objective: Sleep disturbances have been observed in a number of chronic inflammatory conditions, such as systemic lupus erythematosus. Previous results from our laboratory showed that when NZB/NZWF1 mice, an experimental model of lupus, are submitted to sleep deprivation (SD), they exhibit an earlier onset of the disease. Sleep disturbances have far-reaching effects on the endocrine and immune system, changes that may be linked to disease manifestation. Immunoendocrine communication via the hypothalamic-pituitary-adrenal axis has been proposed as an important modulatory factor for the development of autoimmune disease. We hypothesized here that corticosterone (CORT) could be involved in earlier onset of the disease in sleep-deprived NZB/NZWF1 mice. Methods: The profile of CORT secretion was measured immediately after the end of SD (platform method) and during the development of the disease. Also, we analyzed the effects of SD on CORT secretion of Swiss albino mice, which do not present immune alterations. Results: The results showed that NZB/NZWF1 mice exhibited a CORT response to SD similar to Swiss albino mice. However, CORT levels remained elevated throughout the whole period of evaluation. There was an increase in circulating levels of CORT in the NZB/NZWF1 mice as the disease progressed, but this effect was more evident in the sleep-deprived mice. Conclusion: According to these results, we suggest that elevated CORT levels are involved in the earlier onset of the disease.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.